Scientific Publication – Rare Cell Population
10.04.2020. SanoLibio announces the publication of an exhaustive review about blood circulating rare cell types introducing the idea of a diagnostically exploitable rare cell population. Stefan Schreier, the article’s first author suggests that current knowledge of rare cells in the blood is just the tip of the iceberg holding tremendous diagnostical potential for advancing the entire liquid biopsy field based on the rare cell population.
Patent Application – Bone Marrow Damage
20.03.2020 As part of the immanent advancement of cell-based liquid biopsy, we are happy to announce the filing of the latest patent application of the SanoLibio Project introducing the discovery of new blood circulating rare cell types. We are developing a group of new cellular biomarkers to grade bone marrow damage from the blood mainly for cancer diagnostics. Therefore, our assay is potentially replacing bone marrow biopsy or aspiration for diagnostic purposes. The diagnostic realization operates in the early cancer setting and allows a highly sensitive view into distant invasiveness but more importantly into the agressiveness of an individual tumor. We will be able to correctly stage early phase cancer patients and predict relapsing based on tumor evolution rather than statistics as it currently done by molecular analysis of the primary tumor. We will vastly improve cancer diagnosis impacting therapy decision making and consequently patient outcome and benefit.